Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1

Oliveira, Lisa; Geller, Mauro; Cunha, Karin Soares Gonçalves; Santos, Aritânia Sousa; Bernacchi, Allan; Rubenstein, Allan E.; Takirambudde, Sanyu; Mezitis, Spyros G.E.; Brum, Carolina de Almeida Ito; Darrigo, Luiz Guilherme; Ribeiro, Márcia Gonçalves

doi:10.1016/j.heliyon.2021.e06518

Cited by 6 publications

(3 citation statements)

References 38 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase II study with topical liquid diclofenac following laser microporation of CN showed no significant alterations regarding the presence of tissue necrosis, size, or histopathological features of neurofibromas in 6 participants. 41 …”

Section: Resultsmentioning

confidence: 99%

Clinical trials targeting neurofibromatoses-associated tumors: a systematic review

Souza

Abdalla

Mahadevan

2022

Neuro-Oncology Advances

View full text Add to dashboard Cite

Background There is a paucity of literature that comprehensively analyzes previous and current clinical trials targeting neurofibromatoses-related tumors. This article aims to provide readers of drug development efforts targeting these tumors by analyzing translational and clinical findings. Methods This systematic review was written according to the PRISMA guidelines. Inclusion criteria were clinical trials involving patients with neurofibromatosis type 1, type 2, or schwannomatosis that were treated with therapies targeting neurofibromatoses-associated tumors and that were registered on clinicaltrials.gov. In addition, a search was performed in PubMed, Web of Science, Google Scholar, and Embase European for articles fully describing these clinical trials. Results A total of 265 clinical trials were registered and screened for eligibility. Ninety-two were included in this systematic review involving approximately 4,636 participants. The number of therapies analyzed was more than 50. Drugs under investigation mainly act on the MAPK/ERK and PI3K/AKT/mTOR pathways, tumor microenvironment, or aberrantly over-expressed cell surface receptors. Selumetinib was the most effective medication for treating a neurofibromatosis type 1-associated tumor with approximately 68-71% partial response for inoperable or progressive plexiform neurofibromas in children 2 years of age and older and bevacizumab for a neurofibromatosis type 2-related tumor with approximately 36-41% partial response for vestibular schwannomas in patients 12 years of age and older. Conclusions This systematic review presents the results of previous clinical investigations and those under development for neurofibromatoses-associated tumors. Clinicians may use this information to strategize patients to appropriate clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical trials targeting neurofibromatoses-associated tumors: a systematic review

Souza

Abdalla

Mahadevan

2022

Neuro-Oncology Advances

View full text Add to dashboard Cite

show abstract

“…However, these treatments have shown limited success in cNFs to date. cNF microporation using a laser device followed by topical application of diclofenac in six patients (NCT03090971) did not meet its endpoints (Oliveira et al, 2021). Direct injections of ranibizumab, an anti-VEGF mAb, resulted in variable responses (NCT00657202).…”

Section: Topical and Intralesional Treatmentsmentioning

confidence: 99%

Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas

Ly,

Romo,

Gottesman

et al. 2023

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…However adverse events were common and larger study populations followed over a longer period of time are required. A small study testing the efficacy of cNF microporation with a laser device followed by topical treatment with diclofenac, a non-steroidal anti-inflammatory drug, showed no reduction in cNF size and no histological changes (Oliveira et al 2021). However, this was a small study (6 patients) and lack of response may have been due to drug penetration issues.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Insights into the Pathogenesis of NF1-Associated Neoplasms

Bui¹,

Jiang²,

McKay³

et al. 2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1

Cited by 6 publications

References 38 publications

Clinical trials targeting neurofibromatoses-associated tumors: a systematic review

Clinical trials targeting neurofibromatoses-associated tumors: a systematic review

Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas

Insights into the Pathogenesis of NF1-Associated Neoplasms

Contact Info

Product

Resources

About